Replies to post #120746 on Biotech Values

[oldberkeley]

I could also see Teva suing the FDA in that situation...

Win or lose, that strategy always makes me consider the creation of some sort of "goodwill deficit."

Certainly Copaxone is hugely important to Teva, but as the largest generic drug manufacturer and one of the largest pharma companies in the world, they're going to have to work with the FDA on many, many other drugs in the future.

[DewDiligence]

I could also see Teva suing the FDA in that situation, as SNY did re Lovenox.

Unlikely, IMO. In addition to the point raised by OB in #msg-63698660, Teva’s suing the FDA would be inconsistent with Teva’s desire to settle the Copaxone litigation with NVS/MNTA and thereby ensure a little more time with market exclusivity. Teva’s situation with Copaxone is fundamentally different from SNY’s situation with Lovenox, where a settlement with NVS/MNTA was no longer possible.